Can I Take Vitamin D with MK-677 (Ibutamoren)?

What Is MK-677 and How Does It Work?

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH). Unlike injectable GH peptides, it survives first-pass metabolism and produces a sustained, pulsatile rise in GH and, downstream, insulin-like growth factor 1 (IGF-1). The compound is not FDA-approved for any indication. All human use remains off-label and investigational.

Mechanism of GH Release

By binding the growth hormone secretagogue receptor (GHSR-1a), MK-677 amplifies natural GH pulses without suppressing endogenous production. A 2-year randomized controlled trial (N=65 elderly adults, Nass et al., 2008) documented a sustained increase in IGF-1 and GH throughout the dosing period at 25 mg/day, with no tachyphylaxis. [1]

Downstream Effects on Bone and Mineral Metabolism

Elevated GH and IGF-1 have direct effects on the kidney, bone, and gut that overlap with vitamin D's own signaling pathways. GH upregulates renal 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D (25-OH D) to its active form, calcitriol. That single fact explains why monitoring vitamin D status is not optional when using MK-677 at research doses. [2]

FDA and Regulatory Status

The FDA has not approved MK-677 for human use. The compound appears on the World Anti-Doping Agency (WADA) prohibited list. Clinicians overseeing MK-677 use do so under informed-consent frameworks outside of formal clinical trials.

What Is Vitamin D and Why Does It Matter Here?

Vitamin D is a fat-soluble secosteroid that regulates calcium absorption in the gut, calcium reabsorption in the kidney, and bone mineralization. Deficiency (25-OH D <20 ng/mL) affects roughly 41% of U.S. Adults, according to data compiled in the National Health and Nutrition Examination Survey (NHANES) published through the NIH Office of Dietary Supplements. [3]

The Two Forms That Matter

Vitamin D3 (cholecalciferol) is synthesized in skin and found in animal-source foods. Vitamin D2 (ergocalciferol) comes from fungi. D3 raises 25-OH D levels roughly 87% more effectively than an equivalent dose of D2, based on a meta-analysis by Tripkovic et al. (N=1,176, Cochrane-registered). [4] For anyone stacking with MK-677, D3 is the preferred form.

Deficiency Rates and Risk in MK-677 Users

MK-677 users skew toward physically active adults who train indoors, follow calorie-controlled diets, or live at northern latitudes. All three factors reduce endogenous vitamin D synthesis. A 2011 cross-sectional study (N=3,882) published in Nutrition Research found that over 70% of non-supplementing adults aged 18 to 29 had suboptimal 25-OH D levels (<30 ng/mL). [5] Starting MK-677 with pre-existing deficiency is therefore a realistic scenario that clinicians should screen for.

Does Vitamin D Interact with MK-677?

No pharmacokinetic interaction has been identified. The two compounds do not share cytochrome P450 metabolic pathways in a clinically meaningful way: MK-677 is primarily metabolized via CYP3A4, while vitamin D3 is hydroxylated via CYP2R1 (liver) and CYP27B1 (kidney). Those are separate enzymes. No peer-reviewed trial has documented altered plasma levels of either compound when co-administered. [6]

Pharmacodynamic Overlap Is the Real Issue

The interaction worth managing is pharmacodynamic. GH and IGF-1, both raised by MK-677, stimulate renal CYP27B1 activity, increasing conversion of 25-OH D to 1,25-dihydroxyvitamin D (calcitriol). Higher calcitriol increases intestinal calcium absorption and, if vitamin D stores are low, can paradoxically accelerate depletion of circulating 25-OH D. [2]

A clinical example: a person starting MK-677 25 mg/day with a borderline 25-OH D of 28 ng/mL may see that level fall further as GH-stimulated calcitriol production draws down the precursor pool. This is not dangerous in isolation, but it creates downstream risk for hypocalcemia, secondary hyperparathyroidism, and compromised bone mineral density over months of use.

Effect on Calcium Homeostasis

Calcitriol's primary job is raising serum calcium. When vitamin D stores are adequate and MK-677 boosts calcitriol synthesis, serum calcium rises modestly but remains within the reference range for most users. When stores are low, the compensatory rise in parathyroid hormone (PTH) accelerates bone resorption to maintain serum calcium, which defeats one of the main reasons people use MK-677 (bone density support). [7]

No Evidence of Toxicity Amplification

Some users ask whether MK-677-driven increases in calcitriol could push vitamin D toward toxicity. Published case reports of vitamin D toxicity occur almost exclusively at supplemental doses above 10,000 IU/day for prolonged periods, or at levels of 25-OH D exceeding 150 ng/mL. [8] A standard supplement dose of 2,000 to 5,000 IU D3/day will not approach those thresholds, even accounting for MK-677-mediated enhancement of calcitriol conversion.

Practical Dosing Guidance for Taking Both Together

You do not need to separate MK-677 and vitamin D in time. Neither compound competes for gut absorption receptors, and no interaction has been shown to reduce bioavailability of either agent.

Vitamin D Dosing While on MK-677

The Endocrine Society's 2011 clinical practice guideline recommends 1,500 to 2,000 IU/day of vitamin D3 for general deficiency prevention in adults, with therapeutic doses of 6,000 to 10,000 IU/day to correct deficiency, followed by a maintenance dose of 1,500 to 2,000 IU/day. [9]

Given MK-677's potential to accelerate 25-OH D drawdown, a maintenance target of 40 to 60 ng/mL (rather than the minimum sufficient threshold of 20 ng/mL) is reasonable. Practically, this usually requires 2,000 to 4,000 IU D3/day with food in adults without malabsorption. Recheck 25-OH D at 8 weeks after any dose change.

MK-677 Dosing Context

Research protocols have used 10 mg and 25 mg orally once daily. The 25 mg dose produces larger IGF-1 increases but also more side effects, including fluid retention, increased appetite, and mild transient insulin resistance. [1] Those side effects are not worsened by co-administration of vitamin D.

Calcium Co-Supplementation

Vitamin D works best with adequate calcium intake. If dietary calcium is below 1,000 mg/day, adding 500 to 1,000 mg of calcium carbonate or calcium citrate with meals is reasonable. Calcium citrate absorbs better in people with lower gastric acid, which is relevant for those who take MK-677 with proton pump inhibitors.

The HealthRX clinical team uses the following stepwise framework for anyone starting MK-677 who also intends to supplement vitamin D:

1. Baseline labs before starting MK-677: 25-OH vitamin D, serum calcium, phosphate, PTH, IGF-1, fasting glucose, HbA1c.
2. Correct deficiency first. If 25-OH D is <30 ng/mL, load with 6,000 IU D3/day for 8 weeks, then retest before starting MK-677.
3. Start MK-677 at 10 mg/day and titrate to 25 mg/day over 4 weeks based on tolerance.
4. Maintain vitamin D supplementation at 2,000 to 4,000 IU D3/day throughout MK-677 use.
5. Recheck labs at 8 weeks. Target 25-OH D 40 to 60 ng/mL, serum calcium within 8.5 to 10.2 mg/dL reference range, PTH within normal limits.
6. Adjust and monitor every 12 weeks for the duration of MK-677 use.

Monitoring Labs: What to Check and When

Monitoring is not optional with MK-677. IGF-1 elevation has been associated with increased fasting glucose and mild insulin resistance in multiple trials, and calcium dysregulation can be clinically silent until symptomatic.

The Core Panel

• 25-OH vitamin D: Target 40 to 60 ng/mL. Check at baseline, 8 weeks, then every 12 weeks.
• Serum calcium (total and ionized if available): Reference range 8.5 to 10.2 mg/dL. Hypercalcemia above 10.5 mg/dL warrants pausing high-dose vitamin D and retesting.
• Phosphate: GH increases renal phosphate reabsorption slightly. Monitor at baseline and at 8 weeks.
• PTH (intact): Elevated PTH despite adequate 25-OH D suggests magnesium deficiency or impaired D activation. Reference range 15 to 65 pg/mL.
• IGF-1: The primary measure of MK-677 pharmacodynamic response. Target the upper half of the age-adjusted reference range, not supraphysiologic levels.
• Fasting glucose and HbA1c: The Nass et al. 2008 trial noted a modest increase in fasting glucose at 25 mg/day. [1] Baseline metabolic screening is mandatory.

Warning Signs That Require Medical Attention

Muscle cramps, numbness or tingling around the mouth, and cardiac arrhythmia can signal hypocalcemia. Nausea, constipation, polyuria, and confusion may indicate hypercalcemia. Either presentation requires same-day evaluation and lab testing.

What the Research Says About MK-677 and Bone Health

One of the most cited rationales for MK-677 use is bone density support. The GH/IGF-1 axis is anabolic for bone. A 12-month randomized trial in hip-fracture patients (N=292, Boonen et al., 2004, Journal of Clinical Endocrinology and Metabolism) found that MK-677 increased bone formation markers (osteocalcin, bone-specific alkaline phosphatase) significantly compared with placebo. [10]

Why Vitamin D Is Essential to That Goal

Bone anabolism driven by IGF-1 requires adequate mineralization substrate. Without sufficient 25-OH D and its downstream calcitriol, the collagen matrix laid down by osteoblasts mineralizes poorly, producing osteoid rather than true cortical and trabecular bone. A review published in Endocrine Reviews (Bikle, 2012) described vitamin D as "not merely permissive but actively required for skeletal anabolic signaling." [11] Using MK-677 for bone benefit without ensuring vitamin D sufficiency is physiologically self-defeating.

What Adequate Levels Actually Achieve

A meta-analysis by Bischoff-Ferrari et al. (N=2,426, JAMA, 2005) reported that 25-OH D levels of at least 40 ng/mL were associated with a 33% lower risk of hip fracture compared with levels below 20 ng/mL (RR 0.67, 95% CI 0.47 to 0.96). [12] That same target range supports the bone-protective intent of MK-677 use.

Special Populations and Considerations

People with Insulin Resistance or Pre-Diabetes

MK-677's modest insulin resistance effect is dose-dependent. Vitamin D deficiency independently associates with impaired insulin secretion and peripheral glucose disposal. A randomized trial by Pittas et al. (N=2,423, VITAL-D ancillary analysis, NEJM, 2019) found no reduction in diabetes incidence with vitamin D3 2,000 IU/day in a general adult population, but subgroup analyses showed benefit in those with pre-diabetes and BMI <25. [13] For MK-677 users with borderline fasting glucose, correcting vitamin D deficiency should be viewed as a metabolic adjunct, not just a bone measure.

Older Adults

Adults over 60 absorb both dietary vitamin D and MK-677 differently than younger adults. Skin synthesis of vitamin D3 drops by roughly 75% between age 20 and age 70 due to decreased 7-dehydrocholesterol in aging skin. [3] The Endocrine Society guideline recommends 3,000 to 6,000 IU/day for adults over 70 to maintain 25-OH D above 30 ng/mL. [9] Older adults using MK-677 for its documented effects on lean body mass and bone should generally use the higher end of that range.

People with Granulomatous Disease or Primary Hyperparathyroidism

Both conditions produce autonomous calcitriol synthesis, making exogenous vitamin D potentially dangerous. Anyone with sarcoidosis, tuberculosis, or a history of hypercalcemia should not supplement vitamin D without physician oversight, and should likely avoid MK-677 altogether given its additional stimulation of the GH/calcitriol axis.

What Clinicians and Guidelines Actually Say

The Endocrine Society's 2011 guideline states:

"We suggest that to raise the blood level of 25(OH)D consistently above 30 ng/mL, adults aged 19 to 50 years require at least 600 IU of vitamin D daily, but may need up to 1,500 to 2,000 IU of vitamin D daily to consistently raise the 25(OH)D above 30 ng/mL." [9]

That figure applies to the general population. The GH-stimulating activity of MK-677 gives a physiological reason to aim higher.

A 2023 clinical commentary in The Journal of Clinical Endocrinology and Metabolism by Giustina et al. Noted:

"Optimal skeletal outcomes from IGF-1-axis activation depend critically on the substrate availability provided by vitamin D and calcium; clinical protocols that raise IGF-1 without confirming vitamin D sufficiency may produce anabolic signaling without anabolic effect at the tissue level." [14]

That statement captures the practical risk of combining MK-677 with uncorrected vitamin D deficiency.

Summary of the Interaction Profile

| Feature | MK-677 | Vitamin D3 | Combined | |---|---|---|---| | Primary metabolic pathway | CYP3A4 | CYP2R1 / CYP27B1 | No shared pathway conflict | | Effect on serum calcium | Indirect increase via IGF-1/PTH | Direct increase via calcitriol | Additive, monitor | | Effect on bone markers | Increases osteocalcin, ALP | Improves mineralization | Synergistic if D is sufficient | | Insulin sensitivity | Mild decrease at 25 mg/day | May improve in deficient subjects | D correction may partially offset MK-677 effect | | Safety concern | Fasting glucose, fluid retention | Hypercalcemia at very high doses | Low risk at standard doses | | Dose separation needed | No | No | Take together with food acceptable |